SCRI at the 2025 ASCO® Annual Meeting
-
Check out our Accepted Abstracts and Presentations
-
Learn about our Expansive Network
-
Read the Press Release
-
Meet our Research Leaders
-
Learn more about SCRI in our Annual Impact Report
-
Find us at our Booth #27022
Colleagues from across SCRI's network will share research insights with oncology leaders from around the globe.
-
Check out our Accepted Abstracts and Presentations
-
Learn about our Expansive Network
-
Read the Press Release
-
Meet our Research Leaders
-
Learn more about SCRI in our Annual Impact Report
-
Find us at our Booth #27022
155+
Accepted Abstracts & Presentations
75+
Co-Authors Across SCRI
55
Early Phase Studies Featured
75+
Sponsors Represented
20+
Research Sites Represented Through Selected Abstracts & Presentations
Noteworthy Presentations by SCRI Experts
If you are member of the media who is interested in speaking with an expert from SCRI, please contact Becca Gelman at Becca.Gelman@SCRI.com.
Experts from across SCRI’s network will discuss the latest research findings that cover a variety of topics including:
Blood Cancer
David Andorsky, MD, SCRI at Rocky Mountain Cancer Centers I The US Oncology Network, will present “Efficacy and Safety of Asciminib in Patients with Chronic-Phase Chronic Myeloid Leukemia after 1 Tyrosine Kinase Inhibitor: Interim Analysis of the Phase 2 ASC2ESCALATE Trial” in the Rapid Oral Abstract Session, Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant on Friday, May 30 at 2:06 p.m. CDT in E450a.
Breast Cancer
Erika Hamilton, MD, SCRI, will deliver two oral presentations, including “Vepdegestrant, a PROTAC Estrogen Receptor Degrader, vs Fulvestrant in ER-Positive/Human Epidermal Growth Factor Receptor 2 –Negative Advanced Breast Cancer: Results of the Global, Randomized, Phase 3 VERITAC-2 Study” in the Oral Abstract Session, Breast Cancer—Metastatic on Saturday, May 31 at 1:15 p.m. CDT in Hall B1 and “Initial Phase 1 Dose Escalation Data for Emiltatug Ledadotin , a Novel B7-H4-Directed Dolasynthen Antibody-Drug Conjugate” during the Rapid Oral Abstract Session, Development Therapeutics—Molecularly Targeted Agents and Tumor Biology on Monday, June 2 at 8 a.m. CDT in S406.
Cancer Detection
Dax Kurbegov, MD, HCA Healthcare Sarah Cannon Cancer Network, will present “Performance Evaluation of a Reflex Blood-Based Methylated ctDNA Multi-Cancer Early Detection Test in Individuals with Obesity” in the Clinical Science Symposium, The Future of Cancer Detection is Coming on Saturday, May 31 at 8:24 a.m. CDT in Hall D1.
Lung Cancer
David Spigel, MD, SCRI, will present “An International, Multicenter, Prospective Randomized Trial of Adjuvant Chemotherapy for Stage Ia-IIa Non-Small Cell Lung Cancer Identified as High-Risk by a 14-Gene Molecular Assay” in the Poster Session, Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers on Saturday, May 31 from 1:30 – 4:30 p.m. CDT, Hall A.
Solid Tumors
Judy Wang, MD, SCRI at Florida Cancer Specialists & Research Institute, will deliver “An Open-Label, Phase I Trial of The SIRPα Monoclonal Antibody, BI 770371, Alone and in Combination with The PD-1 Inhibitor Ezabenlimab in Patients with Advanced Solid Tumors” as part of the Rapid Oral Abstract Session, Development Therapeutics—Immunotherapy on Sunday, June 1 at 11:45 a.m. CDT in S406.
We Look Forward to Seeing You!
We hope to see you in person at the 2025 ASCO® Annual Meeting. Join us for our “Meet the Expert” series at our Booth #27022, where colleagues and experts including physician leaders from across the SCRI network will be on site daily to answer your questions and share their knowledge. Check out the calendar!
Learn More About Accelero
Our accelerated operations model, Accelero maximizes all parts of SCRI to accelerate drug development and optimize clinical trial delivery. Coordinated through our CRO, SCRI Development Innovations, Accelero enhances connectivity to SCRI research sites, which in turn maximizes site contributions, optimizes site activation timelines, and synchronizes end-to-end clinical research management. Learn more.
